API
< Back to all clusters
[HEALTH] · United States · 3 sources

started · updated

Grail's Galleri cancer blood test nears FDA approval

Grail’s Galleri cancer blood test is approaching a potential FDA approval following a recommendation from an advisory panel. The Molecular and Clinical Genetics Devices Panel voted unanimously that the test is safe, while a majority of members voted that its benefits outweigh its risks.

However, the test remains a subject of scientific debate. Dr. H. Gilbert Welch of Brigham and Women’s Hospital has argued against approval, stating that the primary trial for the test failed to meet its main goal of reducing late-stage cancer diagnoses. While Grail’s CEO, Dr. Josh Ofman, maintains that the clinical evidence is strong—noting the test identifies significantly more cancers at earlier stages—some researchers caution there is currently no definitive proof that the test reduces overall cancer mortality.

If approved, the test faces significant economic hurdles. Currently, patients pay out-of-pocket for Galleri, with costs around $949. While a new US law could make FDA-approved tests eligible for Medicare coverage by 2028, widespread insurance reimbursement remains uncertain. Analysts suggest the US market for such tests could reach between $18 billion and $30 billion over the next decade.

Entities

Dr. H. Gilbert Welch · Dr. Josh Ofman · FDA · GRAIL · Galleri